Near the end of the 20th century, research aiming at exploiting NP as a resource for drug discovery seriously declined. Many pharmaceutical companies concentrated their efforts on new technologies such as combinatorial chemistry, metagenomics and high-throughput screening to generate new drug candidates.

  

However, these new strategies have not delivered the expected results and recently there has been a renewed interest in the use of NP in drug discovery.

In the present Cost Action we will treasure and exploit CM0804 (http://www2.uef.fi/fi/chembionat ) outcomes to develop confirmed leads and pre-clinical candidates of pharmaceutical relevance derived from natural products.